{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-094609","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.076491+00:00","generated_at":"2026-05-31T07:02:25.567038+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers","bullets":["FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.","CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.","Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.","Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-094609","json":"https://secwatch.observer/filing/0001104659-24-094609.json","markdown":"https://secwatch.observer/filing/0001104659-24-094609.md","text":"https://secwatch.observer/filing/0001104659-24-094609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/0001104659-24-094609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/tm2422951d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:02:25.567038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}